1. Home
  2. CBIO vs KLTR Comparison

CBIO vs KLTR Comparison

Compare CBIO & KLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • KLTR
  • Stock Information
  • Founded
  • CBIO 2003
  • KLTR 2006
  • Country
  • CBIO United States
  • KLTR United States
  • Employees
  • CBIO N/A
  • KLTR N/A
  • Industry
  • CBIO
  • KLTR EDP Services
  • Sector
  • CBIO
  • KLTR Technology
  • Exchange
  • CBIO Nasdaq
  • KLTR Nasdaq
  • Market Cap
  • CBIO 308.0M
  • KLTR 302.6M
  • IPO Year
  • CBIO N/A
  • KLTR 2021
  • Fundamental
  • Price
  • CBIO $14.29
  • KLTR $1.63
  • Analyst Decision
  • CBIO Strong Buy
  • KLTR Buy
  • Analyst Count
  • CBIO 5
  • KLTR 3
  • Target Price
  • CBIO $25.60
  • KLTR $2.83
  • AVG Volume (30 Days)
  • CBIO 98.3K
  • KLTR 277.5K
  • Earning Date
  • CBIO 07-31-2025
  • KLTR 08-07-2025
  • Dividend Yield
  • CBIO N/A
  • KLTR N/A
  • EPS Growth
  • CBIO N/A
  • KLTR N/A
  • EPS
  • CBIO N/A
  • KLTR N/A
  • Revenue
  • CBIO N/A
  • KLTR $181,350,000.00
  • Revenue This Year
  • CBIO N/A
  • KLTR $3.43
  • Revenue Next Year
  • CBIO N/A
  • KLTR $2.96
  • P/E Ratio
  • CBIO N/A
  • KLTR N/A
  • Revenue Growth
  • CBIO N/A
  • KLTR 2.56
  • 52 Week Low
  • CBIO $10.83
  • KLTR $1.06
  • 52 Week High
  • CBIO $21.40
  • KLTR $2.82
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 52.92
  • KLTR 48.46
  • Support Level
  • CBIO $13.50
  • KLTR $1.38
  • Resistance Level
  • CBIO $16.00
  • KLTR $1.66
  • Average True Range (ATR)
  • CBIO 0.79
  • KLTR 0.09
  • MACD
  • CBIO 0.16
  • KLTR 0.02
  • Stochastic Oscillator
  • CBIO 39.68
  • KLTR 85.71

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About KLTR Kaltura Inc.

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.

Share on Social Networks: